Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Friend
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 2.17
- Country
- AU
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.51
Financials
Revenue
$0.00-100.0%Net Income
$-12.32MEBITDA
$-13.30MFree Cash Flow
$-9.07MEPS (diluted)
$-3.95Shares Outstanding (diluted)
3.12M+15964.8%Operating Expenses
$13.30MCash & Debt
$69.39MRevenue by Segment (annual)
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.0K | $-20.70M | $-18.90 |
| 2024 | $2.31M | $-26.78M | $-55.00 |
| 2023 | $555.00 | $-20.47M | $-55.00 |
| 2022 | $10.0K | $-25.01M | $-95.00 |
| 2021 | $15.18M | $-8.42M | $-35.80 |
| 2020 | $988.1K | $-12.47M | $-80.00 |
| 2019 | $1.6K | $-10.27M | $-85.60 |
| 2018 | $13.1K | $-6.04M | $-59.80 |
| 2017 | $8.79M | $-10.67M | $-109.30 |
| 2016 | $4.07M | $-12.06M | $-135.20 |
| 2015 | $89.0K | $-7.14M | $-143.45 |
| 2014 | $87.0K | $-7.47M | $-226.25 |
| 2013 | $1.07M | $-1.03M | $-42.70 |
| 2012 | $2.45M | $1.31M | $64.15 |
Valuation
KZIAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (2)
- Newsprnewswire.com·5h ago·Neutral
Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"), each representing five h…
View source ↗ - Newsprnewswire.com·5h ago·Neutral
…Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with St…
View source ↗
Earnings
Fri, Sep 4(in 7 days)
Consensus estimate $-0.65 per share
Typical surprise -27.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Mar 16$-0.58 vs $-0.01miss
- Fri, Nov 7$-0.43 vs $-0.01miss
- Wed, May 28$-7.61 vs $-10.76beat
- Tue, Nov 19$-20.81 vs $-15.00miss
- Mon, Sep 16$-0.30 vs $-3.00beat
- Mon, Nov 27$-10.02 vs $-1.66miss
Estimates and results for KZIA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KZIA officers and directors.
- Bought
- $13.1m
- Sold
- $1.5m
55 trades
13 trades
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.